CORE (TIMI 72a)

CORE is a phase 3 multicenter, randomized, double-blind, placebo-controlled trial of ~450 patients to evaluate the safety and efficacy of ISIS 678354, an antisense oligonucleotide inhibitor of apoC-III production, administered subcutaneously to patients with severe hypertriglyceridemia. CORE on ClinicalTrials.gov Contact Us about CORE